The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring for double-digit market share for them, Biocon Biologics CEO Shreehas Tambe ...

CEO of Biocon Biologics. The US, which contributes 40 per cent of the company’s revenue has a limited risk due to Biocon’s Biologics’s market diversification, coupled with the company’s ...

Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition ...

The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring for double-digit market share for them, Biocon Biologics CEO Shreehas Tambe ...

HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes ...

DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...

Biocon is engaged in the production of therapies ... through its flagship 'Uttam' brand, the company offers a one-stop solution for farming needs, providing urea, DAP, MOP, NPK fertilizers ...

(Image: Freepik) The share price of Biocon rose almost 4% to an intra-day high of Rs 370.90 despite reporting a fall of 96.2% year-on-year in the third quarter of FY25. The company reported a net ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

The regulator found that Goldman Sachs’ acquisition of optionally convertible debentures (OCDs) in Biocon, which would have translated to a 3.81 per cent stake in the company on a fully diluted ...